CFM
NUVB icon

Catalyst Funds Management’s Nuvation Bio NUVB Stock Holding History

Catalyst Funds Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.5K Buy
+10,600
New +$59.1K 0.01% 547
2025
Q4 		– Sell
-94,800
Closed -$351K – 506
2025
Q3 		$351K Buy
+94,800
New +$258K 0.05% 301
2024
Q2 		– Sell
-15,000
Closed -$54.6K – 1466
2024
Q1 		$54.6K Buy
+15,000
New +$28.8K 0.02% 538

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Catalyst Funds Management's NUVB Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Nuvation Bio (NUVB) in Q1 2026: 10,600 shares worth $45.5K. The stake represents 0.01% of the portfolio and ranks #547 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in NUVB as recently as Q3 2025.

Catalyst Funds Management first reported a position in NUVB in Q1 2024 and has held it in 3 quarters since. The position peaked at $351K in Q3 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Catalyst Funds Management held 10,600 shares of Nuvation Bio worth $45.5K as of Q1 2026.
  • Nuvation Bio was a new Catalyst Funds Management position in Q1 2026.
  • Nuvation Bio made up 0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #547 holding.
  • Catalyst Funds Management first reported a position in Nuvation Bio in Q1 2024 and has held it in 3 quarters since.
  • Catalyst Funds Management's Nuvation Bio position peaked at $351K in Q3 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.